Bye-bye Chiro-inositol – Myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction

M. Galletta, S. Grasso, A. Vaiarelli*, Scott J. Roseff**

Reproductive Medicine Unit, Hera Association, Catania (Italy)
*Department of Obstetrics and Gyeacology, Messina University (Italy)
**Palm Beach Center for Reproductive Medicine, Wellington, FL (USA)

---

• Gynecology
• Obstetrics

Abstract. – Polycystic ovary syndrome (PCOS) is a multifactorial syndrome affecting 10% of women in reproductive age. Insulin sensitizer agents are the best therapeutic option for PCOS patients; among which there is Inositol.

Inositol is a polyalcohol existing as nine different stereoisomers, two of which have been shown to be insulin mediators: myo-inositol (MI) and D-chiro-inositol (DCI).

So far only MI have been show to be present in the follicular fluid and in a direct comparison between MI and DCI only MI was able to improve oocyte and embryo quality.

Therefore, Could we say “bye-bye D-chiro-Inositol” in the practice of clinical gynecology and reproductive medicine?

Corresponding Author: Marco Galletta, MD; e-mail: gallettamarco @gmail.com